Analyst
TD Cowen
Equibles does not estimate personal net worth.
Tara Bancroft is recorded as Analyst at TD Cowen. Tara Bancroft has spoken on 9 earnings calls and 2 other investor events across 7 companies, most recently for Nektar Therapeutics on October 1, 2026. Those appearances were for Celcuity Inc. (CELC), Geron Corp (GERN), UroGen Pharma Ltd. (URGN), Nektar Therapeutics (NKTR), Vaxcyte, Inc. (PCVX) and 2 other companies. The companies whose calls Tara Bancroft spoke on are classified in the Healthcare sector.
“So thank you for the good questions. your final question will come from the line of jessica fye from jp morgan your line is open please go ahead hey guys good morning thanks for taking our question probably similar kind of vein as some of the other questions um but i'm curious how you guys are thinking about res peg…”
“So I guess what I'd really like to understand is more of what underscores your confidence in the late Q3 shipments. Like, for instance, are you initially launching with the existing clinical supply?”
“I also want to offer my congratulations on the very strong quarter. It obviously far outperformed linear growth metrics that we were all thinking of. So I'm curious to hear in what metric or factor particularly drove that acceleration and growth that you're seeing the most, especially compared to last quarter.”
“And I guess in that feedback that you are hearing in these discussions with physicians, do you think or have any inkling whether they would be willing to potentially use it off-label in mutants ahead of a potential mutant approval if the data are positive?”
TD Cowen
Analyst
Source not stated
CELC
Biotechnology · Healthcare
GERN
Biotechnology · Healthcare
URGN
Biotechnology · Healthcare
NKTR
Biotechnology · Healthcare
PCVX
Biotechnology · Healthcare
NBTX
Biotechnology · Healthcare
